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1. Introduction
Drug discovery is the process by which new candidate drugs are discovered. The chemical
compounds that are present in plants and animals have been an important source of new
bioactive compounds. Also, we can found organisms that live in air, water and soil that we
don`t see, but posses a great variety of chemical that we can use to create new medicines.
Bioactive compounds offer an enormous diversity of chemical structures with strong biolog‐
ic effect; this is one of the reasons why natural products research cannot be replaced by syn‐
thesis chemistry as a source for new bioactive compounds. Actually, more than the half of
currently used medicines came from natural sources or are related to them, specifically in
the situation of anticancer drugs that more than 60% belongs from nature [1].
Based on the experience in this field, it is considered that a chemical compound isolated from natural
origin should be fully assessed in order to be used to combat diseases; in this manner is important to
consider the type of new chemical entities potentially applicable for partial or total synthesis, as well
as its use in different kind of diseases that are treatable with these compounds (2); Therefore is very
important continue the search for new secondarymetabolites potentially usable as drugs by human.
2. Importance of drug discovery
The importance of look for new bioactive compounds to synthesize new drugs it’s based by
a main objective of saving human life that it’s lose by illness. Also, it is important to recog‐
nized that the drug discovery projects, help those countries that target their efforts in this
area to economically and sociality develop themselves, because when chemical compounds
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are discovered from microorganism that lives in natural environments, this chemical can be
exploited industrially and generate more jobs.
Now, the new drugs and innovative procedures are usually able to keep people alive for a
long time with better conditions that would have previously been rapidly fatal, such as can‐
cer and end-stage heart, liver, lung, kidney, and neurologic diseases. As a result, most peo‐
ple in modern countries die from long-term chronic conditions that are characterized by a
prolonged period of distressing symptoms and progressive loss of function.
According with World Health Organization (WHO) of “57 million global deaths in the last re‐
port  in 2008,  36 million (63%),  were  due to  no communicable  diseases  (NCDs).  The four main
NCDs reported are cardiovascular diseases, cancers, diabetes and chronic lung diseases. The burden
of  these  diseases  is  rising  disproportionately  among lower  income  countries  and  populations.  In
2008, nearly 80% of no communicable disease deaths -- 29 million -- occurred in low- and middle-
income countries with about 29% of deaths occurring before the age of 60 in these countries. The
leading causes of NCD deaths in 2008 were cardiovascular diseases (17 million deaths, or 48% of all
NCD deaths), cancers (7.6 million, or 21% of all NCD deaths), and respiratory diseases, including
asthma and chronic obstructive pulmonary disease (4.2 million). Diabetes caused another 1.3 mil‐
lion deaths” [3]. As we can see, in the WHO’s statistic data, there are less number of people
that die with microbial infection, it can be said to thanks to the constant development of
pharmaceutical drugs.
The discovery of new bioactive compounds from microorganism present in the ambient,
needs the previously determination of diversity, because by knowing the kind of microbes
that live in a certain site, we can be able to design strategies and culture methods adapted
for the different types of microorganism present in nature [4]. We can be able to screen
chemical bioactivity only if we can culture the microorganism, because we need the microbi‐
al biomass to obtain the compounds. To culture microorganism from natural sources is not
an easy topics, because, when we try to cultivate bacteria or fungi from substrates and con‐
ditions that are in constant change, and incubate them in a static temperature and nutrients;
many microbes don’t resist this transformation of circumstances and die.
3. Drug resistance bacteria
Some Bacteria can innately be resistant to one or more types of antimicrobial compounds
and other can be capable of acquired. In actuality, it is well know the factors that provoke
mutations in bacteria that create stronger species that are able to survive to the effects of cur‐
rents drugs. Examples of these factors are the unnecessary use of antibiotics by humans, the
use in animal feeds in low doses, availability over-the-counter in many countries, misuse by
health professionals, patient failure to follow prescribed treatment, antibiotic use in agricul‐
ture, aquaria and family pets, eating raw or undercooked foods.
It can be describe several strategies of antibiotics resistance in different bacterial genera.
Pathogens bacteria that have become resistant to the current antibiotic drug are an increas‐
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ing public health problem. Some examples of diseases that have become very hard to treat
with the current drugs are wound infections, septicemia, tuberculosis, pneumonia, and gon‐
orrhea, to name a few. One part of the problem is that bacteria and other microbes that
cause infections are remarkably adaptable and have developed several mechanisms to be
immune to antibiotics and other antimicrobial drugs.
Also, it`s been reported that over-prescription and the improper use of antibiotics has led to the
generation of antibiotic resistance bacteria that use to be susceptible at those antibiotics [5].
4. Mechanisms of bacteria to become antibiotics resistant
a. Avoiding entrance of antibiotic into the bacteria cell: Bacteria and other microbes can
actually change the properties of its membrane by changing its grade of permeability by
reducing the number of ion channels which are the entrance of some drugs to diffuse
into the cells. Another way to get rid of antibiotics in some bacteria is use adenosine tri‐
phosphate (ATP) to obtain energy to activate this ion channels and pump it out of the
cells.
b. Editing transmembrane protein expression: The mechanism of several antibiotics it`s
to interact specifically with molecules in the membrane of the microbes and preventing
it from interacting with other molecules (usually proteins) inside the cell. Some bacteria
respond by changing the chemical structure or the expression of the molecule (replac‐
ing it with another molecule) so that the antibiotic can no longer recognize it or bind to
it.
c. Bacterial enzymes that destroy antibiotics: Some bacteria can be resistant to antibiotics
by neutralizing them directly. For example, some organisms may obtain new genes that
encode proteins like enzymes that neutralize antibiotics agents before they get to their
targets. An example of this enzymes can be found in the β–lactamases like penicillinas‐
es, cephalosporinases, carbenicillinase, cloxacilanase, carbapenamase, metalloenzyme
that destroy the β-lactamics (penicillins, monobactams, carbapenems, and cephalospor‐
ins). The β–lactamases can be isolated from Gram Negative Bacteria: Escherichia coli, En‐
terobacter cloacae, Citrobacter freundii, Serrati amarcescens, and Pseudomona aeruginosa. The
mechanism of action of β–lactamases is the breaking of β-lactam ring of the antibiotic,
thus destroying the drug [6]. Other example of this is Pseudomona sp. erithromycinester‐
ases that degrade erythromycin by hydrolysis of the lactone ring of erithromycin [7].
5. Cancer
Cancer is an illness that comprises more than hundred types. This disease appears when old cells
are not replaced by new cells and are accumulated in a mass of tissue known as tumor” [4]. To
cite some statistics data; cancer is responsible for one of every four deaths in the United States.
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It’s second only after heart disease as a cause of death in this country. About 1.2 million Ameri‐
cans were diagnosed with cancer in 1998. Of that number, more than 500,000 are expected to die
of this disease. Cancer can attack anyone, but the chances of getting the disease increase with age.
The most common forms of cancer are skin, lung, colon, breast and prostate cancer. Cancer is a
disorder that affects the genes. There were an estimated 12.7 million cancer cases around the
world in 2008, of these 6.6 million cases were in men and 6.0 million in women. This number is ex‐
pected to increase to 21 million by 2030. Lung cancer is the most common cancer worldwide con‐
tributing nearly 13% of the total number of new cases diagnosed in 2008. Breast cancer (women
only) is the second most common cancer with nearly 1.4 million new cases in 2008 and colorectal
cancer (Figure 1) is the third most common cancer with over 1.2 million new cases in 2008 [8].
Figure 1. Cancer Colorectal HCT-116 cell culture in McCoy medium at 40 X amplification
6. Natural source for drug discovery
6.1. Drug discovery from air microorganisms
The atmosphere its well characterized for possess a good light intensity, extreme tempera‐
ture variations, low concentration of organic matter and water, hence become a very hostile
place for microorganism. However, there are a numerous quantity of microbes founded in
the atmosphere, most of them introduced by human activity.
Bioaerosols are airborne particles that are biological in foundation. Bioaerosols can be
formed from nearly any process that involves biological materials and generates enough en‐
ergy to separate small particles from the larger substance, such as wind, water, air, or me‐
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chanical movement. Plants, soil, water, and animals (including humans) all serve as sources
of bioaerosols and are present in most places where any of these sources live.
Microorganisms are frequently considered passive habitants of the air, dispersing via air‐
borne dust particles (Figure 2). However, latest studies suggest that many airborne microor‐
ganisms are metabolically active, even up to altitudes of 20,000 m. Also, it has been
suggested, that some airborne microbes may modify atmospheric conditions [9].
Figure 2. Fungal strains from air samples in Valle de las Palmas, Mexico.
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Several studies reported a great variety of microorganism present in air samples, for exam‐
ple, a study realized in Mexico, in 2007, showed 21 species of bacteria founded in air sam‐
ples from landfill, some of them are pathogenic and opportunistic bacteria, the most
abundant are Pasteurella haemolytica, Serratia plymuthica, Escherichia coli y Klebsiella pneumonia
and 19 fungal species, 7 of them allergenic, Cladosporium herbarum, Aspergillus sp y Penicilli‐
um sp. [10]. Despite this, Serratia plymuthicait’s well known to possess 2-amino-3-(oxir‐
ane-2,3-dicarboxamido)-propanoyl-valine has been shown to inhibit the growth of the
human pathogen Candida albicans efficiently [11].
Another studies found airborne microbes collected at indoor air with filters installed in two
shopping centers in Singapore. The most common microorganism appears to be several spe‐
cies of Brevundimonas (50%) [12] other study has identified Brevundimonas diminutaas pro‐
ducer of a nematicidal metabolite known as (R)-(-)-2-ethykhexan-1-ol which have a strong
activity against C. elegans and B. xylophilus [13].
6.2. Drug discovery from soil microorganisms
Soil microorganisms (Figure 3), such as bacteria and fungi, play central roles in soil fertility
and promotion of plant health. It is assessed that in 1 g of soil there are 4000 different bacte‐
rial ‘‘genomic units’’ based on culture independent identification methods. In the other
hand, an estimated 1,500,000 species of fungi, but they are more difficult to cultivated by
standard methods [14].
In soil there is a constant exchange of organic substances and flow of energy. Feeding, pre‐
dation, degradation of macromolecular substrates and absorption of nutrients have been im‐
portant in chemical processes in soil. One of the most important microorganism in drug
discovery found in natural habitat mainly in soil are the actinomycetes which are very di‐
verse family of bacteria, they are an important source of bioactive compounds with high val‐
ue in pharmaceutical industry. It’s have been reported that almost 80% of the world`s
antibiotics come from the genera Micromonospora and Streptomyces. Beside this, the majority
of the actinomycetes in soil that are potential drug sources remain uncultivable, and there‐
fore in cannot be screened for novel antibiotic discovery [5].
Has been reported that microorganisms found in soil are a plentiful source of chemically di‐
verse bioactive compounds, and have been an important source for the discovery of antibac‐
terial agents including penicillins, cephalosporins, aminoglycosides, tetracyclines, and
polyketides [2].
Also, from 117 actinomycetes strains isolated from the wasteland alkaline and garden soil
samples in India, were found 15 actinomycetes strain that showed antimicrobial activity
against at least two pathogen bacteria between them Staphylococcus aureus[5].
According to reference [15], environmental factors, such as carbon and energy sources, mineral
nutrients, growth factors, ionic composition, available water, temperature, pressure, air compo‐
sition, electromagnetic radiation, pH, oxidation–reduction potential, surfaces, spatial relation‐
ships, genetics of the microorganisms and interaction between microorganisms, can alter the
microbial diversity, activity and population dynamics of microorganisms in soil. It is important
to mention that almost 80–90% of the microorganisms habiting soil are on solid surfaces [15].
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Figure 3. Bacteria strains from soil samples in Valle de las Palmas, Mexico.
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6.3. Drug discovery from water microorganisms
The world’s oceans comprise about 70 % of the earth’s surface, where the extensive drug
discovery efforts involving soil bacteria have not been extended to this ecosystem [16]. This
environment have special attention since is known that typical microbial abundance of 106
per ml in the water column and 109 per ml in ocean bottom sediments. Actinobacteria is
among the most dominant population and successful phyla of all environments [17]. This
class takes into account 5 subclasses, 9 orders, 55 families, 240 genera and 3000 species [18].
From all actinobacteria, Marine Actinobacteria have become the most important source of
secondary metabolites with medical application, such as anticancer, antibiotics, antitumor,
anti-inflammatory, and antifungal compounds [16-17, 19].
Actinobacteria, called commonly actinomycetes are Gram positive bacteria having a higher
guanine plus cytosine (G+C) percentage in its DNA than any other bacteria. Most of these
organisms are aerobic (oxidative), some are facultative or forced anaerobes (fermentation)
[20]. These microorganisms grow as networks called mycelium. They structures are filamen‐
tous. Sometimes are on the surface, for that is called aerial mycelium, or substrate mycelium
if it attaches to the substrate surface [21]. The individual filaments of the mycelium or hy‐
phae are divided into units as a result of growth of the cell wall into the hyphae at regular
intervals along this structure. This process is called septation and each of the resulting septa
contains one DNA molecule. The mycelium bacterium is analogous to the mycelium form‐
ing filamentous fungi [22]. Actinobacteria produce spores in specialized hyphae many of
which are developed on the aerial filament, sometimes these spores are flagellated. The Acti‐
nobacteria inhabit the soil where play an important role in soil chemistry, the characteristic
odor of soil is due to special metabolites that are known as Geominas [23]. Actinobacteria
also inhabit aquatic environments including those marine. Actinomycetes are the most eco‐
nomically and biotechnologically valuable prokaryotes [24].
Almost 60 years in actinomycetes researches, more than 15000 bioactive compounds have
been discovery for academic and pharmaceutical researchers many of which are used as
drugs today. Fact more than half of the antibiotics discovered to date are obtained from the
soil-derived actinomycete bacteria Streptomyces and Micromonospora genus spores [25].
The majority of the actinomycetes isolated from marine sources was largely of terrestrial ori‐
gin and had been washed to shore and existed in the ocean as metabolically inactive spores
[25]. Recently, phylogenetic analyses of the 16S rRNA genes indicate that existing new taxa
widely distributed in ocean sediments [26], including some that appear to be unique and ob‐
ligate marine actinomycete bacteria [27]. These strains represent the most significant source
of naturally occurring microbial antibiotics [17, 28- 30] and antitumor compounds [28- 30]
with specific metabolic and physiological capabilities that had not been observed in terres‐
trial microorganisms before [31-32]. Members of this group are producers of clinically useful
antitumor drugs such as anthracyclines, glycopeptides,aureolic acids, enediynes, antimeta‐
bolites, carzinophilin, mitomycins and others [19].
The studies related with new biodiversity and drugs discovery had been examined from
waters all around the world such as San Diego Bay, Bahamas, Fiji and Guam Islands among
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others. Recently, one study in the Gulf of California [32] found Operational Taxonomic
Units (OTUs) belonging Streptomyces and Actinomadura genus and a potentially represent a
new genus-level taxon in the family Streptomycetaceae. In addition, several previously descri‐
bed marine species were isolated including Micromonospora krabiensis, Saccharomonospora
marina, Streptomyces fenhuangensis, Verrucosispora maris and Verrucosispora sediminis suggest‐
ing that these species may have broad geographic distributions.
The genes involved in secondary metabolism are responsible for the biosynthesis of small
molecules that mediate important functional traits such as allelopathy, chemical communi‐
cation and iron acquisition [33]. These compounds have been used to assess biogeographical
patterns among bacteria [34].
Polyketide synthase (PKSI) genes are called Type I and are responsible for the production of
many important secondary metabolites including the antibiotic erythromycin [35] and the
anticancer agent epothilone [35-36].
Bacteria can maintain complex assemblies of PKS genes [37], many of which are not ex‐
pressed under normal laboratory conditions [38]. Recently, a study found that HGT plays an
important role in the evolution of PKSI genes and that ketosynthase (KS) domains within
polyketide synthase genes are phylogenetically important making predictions about pro‐
duction of secondary metabolites by complex biosynthetic pathways [39-40]. Other method
used for providing further evidence for endemism associated with secondary metabolites
[33], is the terminal restriction fragment length polymorphism (T-RFLP) used to demon‐
strate that subpopulations of bacteria cluster together based on collection site [41].
According to [32] targeting KS domains provides a rapid method to assess PKS diversity
and novelty within individual strains. The results revealed evidence of common pathways
shared with other Salinispora strains but also sequences that share low levels of identity with
any characterized pathways and thus may be associated with the production of new secon‐
dary metabolites. It is noteworthy that the new sequence type “L” also possesses a KS se‐
quence that has not previously been observed in “S. pacifica”.
Secondary metabolites are linked to an organism’s fitness and therefore represent an emerg‐
ing marker to study population structure and function, taxonomically meaningful patterns
of secondary metabolite production have been detected in bacteria [42] and fungi [43].
Progress has also been made in drug discovery from actinomycetes by using high through‐
put screening and fermentation, metabolic profiling technologies, genome scanning, mining
genomes for cryptic pathways, and combinatorial biosynthesis to generate new secondary
metabolites related to existing pharmacophores [17, 44]. Metagenomic screening of DNA
from environmental samples [45-46] provides an alternative way of discovering new antibi‐
otic biosynthetic genes.
According to [47] recently published new web tools that provide automated methods to assess
the secondary metabolite gene diversity; those are the Natural Product Domain Seeker (NaP‐
DoS) analysis based on the phylogenetic relationships of sequence tags derived from polyketide
synthase and non-ribosomal peptide synthethase (NRPS) genes. These results are compared
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with an internal experimentally database. NaPDoS provides a rapid mechanism used to infer
the generalized structures of secondary metabolites biosynthetic gene richness and diversity
within a genome or environmental sample by extract and classification of ketosynthase and con‐
densation domains from PCR products, genomes, and metagenomic datasets increasing expo‐
nentially the investigations in this field of science with benefits in the field of drug discovery.
Table 1 shows a list of microorganisms isolated from different sources which produce anti‐
oxidant, antibacterial, anticoagulant, antiviral, anti-inflammatory, immune system, antidia‐
betic and nematicidal activities, as well as their action mechanisms.
Microorganism Bioactive
Compounds
Bioactivity Mechanism Reference Natural
Source
Brevundimonas
diminuta
(R)-(-)-2-ethylhexan-1-ol Nematicidal Inhibitor against C. elegans and B.
xylophilus
[48] Air
Pasteurella
haemolytica
A1-Derived Leukotoxin
and Endotoxin
Inmune system Induce Intracellular Calcium
Elevation in Macrophages
[49] Air
Streptomyces strain
PM0324667
NFAT-133 Antidiabetic induced glucose uptake in L6
skeletal muscle cells
[50] Soil
Clostridium
cellulolyticum
Closthioamide Antibiotic Staphylococci
Multiresistente inhibition
[51] Soil
Gordonia sputi DSM
43896
G48 JF905613 Compound Antimicrobial C. albicans, S. aureus inhibition [52] Soil
Actinomycetes 3Ba3 Compound Antibacterial E. amylovora, P. viridiflova,
A. tumefaciens, B. subtilis
ATCC 663, E. coli ATCC 29998 3
inhibition
[53] Soil
Micromonospora sp. Diazepinomicin/
ECO-4601
Antimicrobial Unespecific [54] Soil
Eurotium HerbariorumE. Herbariorum NE-4 Antioxidant Antioxidant in vitro [55] Water
Sponge Batzelladine L y M Antibacterial S. aureus and methicillinresistant,
S. aureus inhibition
[56] Water
Bivalve mollucs Anticoagulant
polypeptide (TGAP)
Anticoagulant Inhibition of factor II toIIa
conversion
[56] Water
Fungus 8′-O-Demethylnigerone Antituberculosis M. tuberculosis inhibition [56] Water
Algae Dolabelladienetriol Antiviral Inhibition of HIV-1
replication
[56] Water
Soft coral Durumolides A-C Anti-inflammatory Modulation of LPS-activated
murine macrophage cell line
[56] Water
Sea cucumber Frondoside A Immune system Lysosomal activity, phagocytosis
and ROS activation
[56] Water
Table 1. Microorganism isolated from natural sources that produce bioactive compounds
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7. Conclusion
Bioactive compounds isolated from aerial, terrestrial and marine organisms have extensive
past and present use in the treatment of many diseases and serve as compounds of interest
both in their natural form and as templates for synthetic modification. To found new com‐
pounds useful to develop new pharmaceutical drugs, a good potential source and diverse
bioactive chemicals is microorganism present in natural sources as air, soil and water.
Chemical compounds from natural sources are the major protagonists in chemical diversity
for pharmaceutical discovery over the past century. The interesting chemicals identified as
natural products are derived from the biodiversity in which the interactions between micro‐
bial entities and their environment formulate the diverse complex chemical entities within
the organisms that enhance their survival and competitiveness. Hence, it is important to
study inter and intraspecific interactions between microorganism in natural environments,
this will make the screening for bioactive compounds in microbes easier.
Microbial interactions can influence the secretion of bioactive compound. Has been report‐
ed, various types of contacts among bacterial species and other organism. For example,
these relations can be negative (parasitism, competition and predation) or positive (metabio‐
sis and symbiosis) for these microorganisms. Between interactions in microorganism we can
emphasize competition. Some bacteria are reduced by different species when the environ‐
mental resources are limited; therefore they produce compounds that impress negatively in
their competitors [4].
Finally, air, soil and water are the home of microorganism that compete all the time to sur‐
vive, resist changes in temperature, pressure, nutrient, carbon and nitrogen content, micro‐
organisms that are obligated to produce weapons against predators, change and mutate to
scape of detection of other microbes. All this, are the reason why we can find an unimagina‐
ble number and variety of chemical that are effective to be part of a pharmaceutical drug
formulation.
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